A Look Ahead: Expert Perspective on CAR-T Cell Therapy vs. Transplant in Myeloma

Published on

Topics include: Treatments

What does the future hold for CAR-T cell therapy and the standard of care for multiple myeloma? Will CAR-T cell therapy replace transplants? Myeloma experts Dr. Amrita Krishnan, from City of Hope, and Dr. Joshua Richter, from Mount Sinai School of Medicine, discuss current clinical trial research and explain how this approach compares to other approved myeloma therapies. What is the patient response? How will CAR-T cell therapy fit in with the current treatment landscape? Watch now to find out more.

This is a Patient Empowerment Network program produced by Patient Power. We thank AbbVie, Inc., Celgene Corporation, and Takeda Oncology for their support.

View more programs featuring , and

Produced in association with

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Jack Aiello:

What we are looking at is the trial that was going to open through the BMT CTN (Blood & Marrow Transplant Clinical Trials Network) is patients that have very, very high-risk myeloma doing CAR-T cells after an autologous transplant. So really in a way you're trying to get the best of both worlds.  

The only type of transplant that limits options for CAR-T is allogeneic stem cell transplant, makes you ineligible for many but not all of the CAR-T protocols.  But, again, the decision of which way to go now is going to change in the future and this is a conversation you should definitely have with your care team.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

CAR T-Cell Therapy: An Expert Weighs the Risks and Benefits

Dr. Nicole Lamanna gives an expert perspective on the current and future status of CAR T-cell therapy for CLL. Who is it approved for? What are the potential toxicities? Watch now to find out more.

Published:

Cherie Rineker: Post-CAR T-Cell Trial for Multiple Myeloma

Myeloma patient Cherie Rineker gives Patient Power an inside look into her experience with a CAR T-cell clinical trial. Watch to learn her highs and lows of the trial.

Published:

Who Will Benefit From CAR T-Cell Therapy?

Tune in to find out from our panel of experts what conditions are suited for CAR T-cell therapy, the duration of the results, and where the treatment fits on your journey with CLL.

Published:

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on October 10, 2018